Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease.

Carmen Peña-BautistaLourdes Álvarez-SánchezRosa PascualMaria José MorenoMiguel BaqueroConsuelo Cháfer-Pericás

Published in: European journal of clinical investigation (2022)

The ratio Aβ42/Aβ40 showed the highest discriminating capacity between AD and non-AD patients and might be useful in clinical practice. Regarding NfL, it is not a specific biomarker for AD; however, it might be helpful for the differential diagnosis of frontotemporal dementia. Nevertheless, further analysis in an external cohort is required in order to validate these results.

Keyphrases

cerebrospinal fluid
clinical practice
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
cognitive decline
mild cognitive impairment